GeneDx (WGS) Insider Joshua Ruch Sells 3,576 Shares

Joshua Ruch sold 3,576 shares of GeneDx Holdings Corp. (NasdaqGS: WGS) on June 18, 2026. Shares of the genomics company traded at $55.42 on Wednesday.

Insider Buying and Selling at GeneDx Holdings Corp.

Several insiders were active on June 18, 2026. Alongside Joshua Ruch, Ryan Jason and Keith Meister also sold 3,576 shares each. Meanwhile, Joshua Ruch, Eli Casdin, and Thomas Fuchs bought 4,248 shares each on the same day.

Other Institutional Activity in GeneDx Holdings Corp.

Corvex Management LP increased its holdings in GeneDx by 169,520 shares, ending with 3,228,149 shares valued at about $207.3 million, a 5.5% increase. ARK Investment Management LLC significantly boosted its position by 720,022 shares, now holding 1,324,583 shares worth approximately $85.1 million, reflecting a 119.1% increase. Westfield Capital Management Co LP also grew its stake by 350,847 shares, reaching a total of 1,369,108 shares valued at $87.9 million, marking a 34.5% increase. In contrast, BlackRock, Inc. trimmed its holdings by 9,386 shares, now holding 1,550,708 shares worth $99.6 million, a slight 0.6% decrease.

GeneDx Holdings Corp. Stock Down 42.6%

Shares of GeneDx Holdings Corp. traded near $55.42 on Wednesday. The company, which operates in the healthcare sector, specifically in diagnostics and research, has a market cap of about $1.65 billion. Its forward P/E ratio stands at 45.01, and it has a beta of 1.971, indicating a higher volatility compared to the market. The stock's 52-week range is between $32.21 and $170.87. GeneDx's 50-day moving average is $54.79, while its 200-day moving average is $99.42. The company maintains a current ratio of 3.088 and a quick ratio of 2.825, with a debt-to-equity ratio of 66.185.

Analysts Set New Price Targets

On June 23, 2026, Piper Sandler maintained its 'buy' rating for GeneDx with a price target of $63. Canaccord Genuity, Wells Fargo, and Guggenheim also maintained their 'buy' ratings in early May, with targets ranging from $75 to $100. The consensus among nine analysts is a 'strong buy,' with a mean price target of $77.

About GeneDx Holdings Corp.

GeneDx Holdings Corp., based in Stamford, Connecticut, is a genomics company specializing in genetic testing services. It focuses on diagnostics for pediatric and rare diseases through whole exome and genome sequencing. The company also develops an AI-based platform for sequencing analysis and clinical reporting. With 1,300 employees, GeneDx serves the healthcare industry by providing critical insights for hereditary risk and cancer testing.

Bottom Line

Joshua Ruch's recent sale of shares in GeneDx Holdings Corp. is part of broader insider activity at the company. Investors often track such moves for potential insights into company performance. While insider transactions can draw attention, they represent only one piece of the broader investment puzzle. GeneDx, with its focus on genomics and diagnostics, remains a company watched closely by institutional investors and analysts alike.